
    
      An initial cohort of 5 subjects will be allocated to Group A. When all subjects enrolled in
      Group A have completed 14 days of post-treatment follow-up, results of donor site
      evaluations, histological analyses and reported adverse events will be reviewed by the
      Investigator and study Sponsor. If the data is suggestive of clinical benefit following
      treatment and absent any serious and/or unexpected adverse events, which are, in the opinion
      of the investigator, related to the treatment, the remaining subjects will be enrolled and
      randomized to Groups B, C or D.
    
  